M
Michael D. Prados
Researcher at University of California, San Francisco
Publications - 466
Citations - 57545
Michael D. Prados is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Glioma & Temozolomide. The author has an hindex of 107, co-authored 444 publications receiving 51418 citations. Previous affiliations of Michael D. Prados include Harvard University & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404.
Michael D. Prados,Michael D. Prados,W. Seiferheld,W. Seiferheld,Howard M. Sandler,Howard M. Sandler,Jan C. Buckner,Jan C. Buckner,Theodore Phillips,Theodore Phillips,Christopher J. Schultz,Christopher J. Schultz,Raul C. Urtasun,Raul C. Urtasun,Richard L. Davis,Richard L. Davis,Philip H. Gutin,Philip H. Gutin,Terrence L. Cascino,Harry S. Greenberg,Harry S. Greenberg,Walter J. Curran,Walter J. Curran +22 more
TL;DR: An open-label, randomized Phase III trial in newly diagnosed patients with anaplastic glioma other than glioblastoma multiforme comparing external beam radiotherapy (EBRT) plus adjuvant procarbazine, cyclohexylchloroethylnitrosurea, and vincristine (PCV) chemotherapy with or without bromodeoxyuridine (BUdR).
Journal ArticleDOI
Phase III trial of accelerated hyperfractionation with or without difluromethylornithine (DFMO) versus standard fractionated radiotherapy with or without DFMO for newly diagnosed patients with glioblastoma multiforme.
Michael D. Prados,William M. Wara,Penny K. Sneed,Michael W. McDermott,Susan M. Chang,Jane Rabbitt,Margaretta Page,Mary Malec,Richard L. Davis,Philip H. Gutin,Kathleen R. Lamborn,Charles B. Wilson,Theodore L. Phillips,David A. Larson +13 more
TL;DR: In this prospective Phase III study, no survival or PFS benefit was seen with accelerated hyperfractionated irradiation to 70.4 Gy, nor was any benefit seen with DFMO as a radiosensitizer, and standard fractionation to 59.4Gy remains the treatment of choice for newly diagnosed patients with glioblastoma multiforme.
Journal ArticleDOI
A prognostic gene expression signature in infratentorial ependymoma
Khalida Wani,Terri S. Armstrong,Terri S. Armstrong,Elizabeth Vera-Bolanos,Aditya Raghunathan,David W. Ellison,Richard J. Gilbertson,Brian Vaillant,Stewart Goldman,Roger J. Packer,Maryam Fouladi,Ian F. Pollack,Tom Mikkelsen,Michael D. Prados,Antonio Omuro,Riccardo Soffietti,Alicia Ledoux,Charmaine D. Wilson,Lihong Long,Mark R. Gilbert,Kenneth Aldape +20 more
TL;DR: The results indicate a link between clinical outcome and biologically identified subsets of infratentorial ependymoma and offer the potential for prognostic testing to estimate clinical aggressiveness in these tumors.
Journal ArticleDOI
Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity
TL;DR: Clinical and pathologic characteristics distinct to gliosarcoma compared to glioblastoma suggest that they may warrant specific treatment, separate from conventional GBM therapy.
Journal ArticleDOI
A preliminary study of the prognostic value of proton magnetic resonance spectroscopic imaging in gamma knife radiosurgery of recurrent malignant gliomas.
Edward E. Graves,Sarah J. Nelson,Daniel B. Vigneron,Cynthia Chin,Lynn J. Verhey,Michael W. McDermott,David A. Larson,Penny K. Sneed,Susan M. Chang,Michael D. Prados,Kathleen R. Lamborn,William P. Dillon +11 more
TL;DR: The pretreatment spectroscopic results provided information that was predictive of outcome for this patient pool, both in local control and global outcome, and this modality may have an important role in improving the selection, planning, and treatment process for glioma patients.